$PMCB PharmaCyte Biotech is currently developing a
Post# of 1086
(Total Views: 4954)
Posted On: 03/25/2017 7:19:28 PM
$PMCB PharmaCyte Biotech is currently developing a treatment for
Type 1 diabetes that is unique among available treatments for this disease.
The Company’s treatment will also be available for those who have Type 2 diabetes where traditional medications are no longer effective.
PharmaCyte Biotech is developing a treatment that encapsulates a human cell line (Melligen cells) engineered to produce and store insulin and secrete it at levels in proportion to the levels of glucose (blood sugar) in the human body. The encapsulation will be done using PharmaCyte’s signature live-cell encapsulation technology, Cell-in-a-Box®.
PharmaCyte Biotech believes that the combination of the Melligen cells and the Cell-in-a-Box® encapsulation technology could lead to a break-through treatment using insulin-producing beta islet cell replacement that will overcome all of the past problems in developing a true bio-artificial pancreas.
PharmaCyte has assembled an International Diabetes Consortium of doctors, scientists and researchers from all over the world to help it develop a successful diabetes treatment.
We would like to thank Stock Market Media Group for documenting the Company’s diabetes story.
Footage provided by:
University of Technology Sydney – UTS Science – Anna Zhu
Monegro Productions
Bay Colony Media
Read More: http://investorshangout.com/post/view?id=4408...z4cNn5OnqN
Type 1 diabetes that is unique among available treatments for this disease.
The Company’s treatment will also be available for those who have Type 2 diabetes where traditional medications are no longer effective.
PharmaCyte Biotech is developing a treatment that encapsulates a human cell line (Melligen cells) engineered to produce and store insulin and secrete it at levels in proportion to the levels of glucose (blood sugar) in the human body. The encapsulation will be done using PharmaCyte’s signature live-cell encapsulation technology, Cell-in-a-Box®.
PharmaCyte Biotech believes that the combination of the Melligen cells and the Cell-in-a-Box® encapsulation technology could lead to a break-through treatment using insulin-producing beta islet cell replacement that will overcome all of the past problems in developing a true bio-artificial pancreas.
PharmaCyte has assembled an International Diabetes Consortium of doctors, scientists and researchers from all over the world to help it develop a successful diabetes treatment.
We would like to thank Stock Market Media Group for documenting the Company’s diabetes story.
Footage provided by:
University of Technology Sydney – UTS Science – Anna Zhu
Monegro Productions
Bay Colony Media
Read More: http://investorshangout.com/post/view?id=4408...z4cNn5OnqN
(0)
(0)PharmaCyte Biotech Inc. (PMCB) Stock Research Links
Scroll down for more posts ▼